Aerosol Therapy in Obese COPD Patients.

Not Applicable

Completed

• Conditions: Chronic Obstructive Pulmonary Disease Moderate; Obesity

• Registration Number: NCT03031093
• Lead Sponsor: Universidade Federal do Rio Grande do Norte

Brief Summary

This study has the objective to clarify the factors that directly influence the effectiveness of inhaled drug deposition in obese patients with chronic obstructive pulmonary disease (COPD) and suggest the use of High Flow Nasal Cannula (HFNC) during their inhalation therapy.

Detailed Description

This study has the objective to clarify the factors that directly influence the effectiveness of inhaled drug deposition in obese patients with chronic obstructive pulmonary disease (COPD) and then formulate specific strategies to control the evolution of this disease. The suggested strategy in order to implement the aerosol therapy is the use of High Flow Nasal Cannula (HFNC) during these patient´s inhalation therapy.

It will consist in a cross-over clinical trial. The population will be composed by volunteers of both genders, aged between 45-70 years old. Four distinct groups will be formed: obese participants without copd; obese participants with copd; non obese participants without copd; non-obese participants with copd.

Study Timeline

• Study First Submitted: 2016-12-06
• Study First Submitted QC: 2017-01-21
• Study First Posted: 2017-01-25
• Study Start: 2017-12-02
• Primary Completion: 2018-04-03
• Study Completion: 2018-05-05
• Status Verified: 2019-10
• Last Update Submitted: 2019-10-21
• Last Update Posted: 2019-10-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

HEALTHY, non obese

• no history of respiratory disease
• non smokers
• self declared sedentary
• Forced expiratory volume at first second (FEV1) equal or higher than 80% of predicted
• Forced Vital capacity (FVC) equal or higher than 80% of predicted;
• FEV1/FVC higher than 70% of predicted.
• BMI lower than 30 kg/m2

HEALTHY, obese

• no history of respiratory disease
• non smokers
• self declared sedentary
• Forced expiratory volume at first second (FEV1) equal or higher than 80% of predicted
• Forced Vital capacity (FVC) equal or higher than 80% of predicted
• FEV1/FVC higher than 70% of predicted.
• BMI equal or higher than 30 kg/m2

COPD participants, non obese

• ex smokers
• clinical stability (six previous weeks)
• FEV1 lower than 80% of predicted.
• FEV1/FVC lower than 70 % post bronchodilator.
• No cardiopulmonary diseases (self declared)
• BMI lower than 30 kg/m2

COPD participants, obese

• ex smokers
• clinical stability (six previous weeks)
• FEV1 lower than 80% of predicted.
• FEV1/FVC lower than 70 % post bronchodilator.
• No cardiopulmonary diseases (self declared)
• BMI equal or higher than 30 kg/m2

Exclusion Criteria

• Difficulty to understand verbal commands
• exacerbations during the study period

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Pattern of aerosol lung deposition.	during the following 25 minutes post inhalation protocol	The pattern of aerosol lung deposition will be compared between obese and non obese participants (with and without COPD) as well as between inhalation with HFNC and without HFNC

Secondary Outcome Measures

Name	Time	Method
Change of pulmonary function after bronchodilators administration. (with and without HFNC)	Change from Baseline Pulmonary Function at 5 minutes after scintigraphy.	pulmonary function will be evaluated previously to the inhalation protocol. After the inhalation protocol, this measurement will be assessed again in order to check the effect of bronchodilator drug.
Muscle Mass	first day of study	Muscle Mass percentage
BMI	first day of study	Body mass index
Upper airways anatomical variables CT scans	first day of study	Upper airways anatomical variables will be measured by CT scans.
Mallampati Score	first day of study	Mallampati Score (from 1 to 4)
Body fat	first day of study	Body fat percentage

Trial Locations

Locations (1)

Universidade Federal de Pernambuco; 🇧🇷 Recife, Pernambuco, Brazil